BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/9/2026 4:15:45 AM | Browse: 1 | Download: 1
 |
Received |
|
2026-04-29 03:21 |
|
Peer-Review Started |
|
2026-04-29 03:24 |
|
First Decision by Editorial Office Director |
|
2026-06-01 07:20 |
|
Return for Revision |
|
2026-06-01 07:20 |
|
Revised |
|
2026-06-19 16:24 |
|
Publication Fee Transferred |
|
2026-07-14 03:29 |
|
Second Decision by Editor |
|
2026-07-29 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-07-29 10:00 |
|
Articles in Press |
|
2026-07-29 10:00 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-09-07 10:50 |
|
Publish the Manuscript Online |
|
2026-11-09 04:15 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy and safety of surufatinib and anti-PD-L1 therapy in combination with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rong-Ce Zhao, Xin-Hao Xiong, Jing Zhou, Liang-He Lu, Jie Mei, Wei Wei and Rong-Ping Guo |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82303879 and No. 82303875 |
|
| Corresponding Author |
Rong-Ping Guo, Professor, Department of Liver Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou 510060, Guangdong Province, China. guorp@sysucc.org.cn |
| Key Words |
Unresectable intrahepatic cholangiocarcinoma; Surufatinib; Anti-programmed cell death-ligand 1; Hepatic arterial infusion chemotherapy; 5-Fluorouracil |
| Core Tip |
Combining surufatinib and anti-programmed death-ligand 1 therapy with hepatic arterial infusion chemotherapy yields promising antitumor activity and survival benefits for unresectable intrahepatic cholangiocarcinoma. This innovative regimen demonstrates a highly favorable safety profile, characterized by a low incidence of grade 3 or 4 adverse events. Notably, patients who respond to this combination therapy achieve significantly better prognostic outcomes compared to non-responders. These findings highlight a potent, well-tolerated therapeutic strategy that could substantially improve clinical management for unresectable intrahepatic cholangiocarcinoma. |
| Publish Date |
2026-11-09 04:15 |
| Citation |
Zhao RC, Xiong XH, Zhou J, Lu LH, Mei J, Wei W, Guo RP. Efficacy and safety of surufatinib and anti-PD-L1 therapy in combination with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma. World J Gastroenterol 2027; 33(1): 122785
|
| URL |
https://www.wjgnet.com/1007-9327/full/v33/i1/122785.htm |
| DOI |
https://doi.org/10.3748/wjg.122785 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
